Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.51 |
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | DUT | P33316 | 4/20 | 0.45 |
| ▸ | TLR4 | O00206 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | ACACA | Q13085 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25818867 | 0.93 | HTR2C (0.50) | KDM5AKDM4CPRMT6ALDH1A1TLR4 | |
| SCHEMBL1409587 | 0.85 | CHRM2 (0.60) | KDM5AKDM4CNOS1CARM1PRMT6 | |
| SCHEMBL22957771 | 0.85 | KDM5A (0.49) | KDM5AKDM4CALDH1A1DUTTLR4 | |
| SCHEMBL11942141 | 0.82 | ALDH1A1 (0.51) | KDM5AKDM4CALDH1A1TLR4TLR2 | |
| SCHEMBL22957824 | 0.80 | KDM5A (0.46) | KDM5AKDM4CALDH1A1DUTTLR4 | |
| SCHEMBL28168876 | 0.80 | KDM5A (0.58) | KDM5AKDM4CACACBACACANR1H4 | |
| SCHEMBL8274392 | 0.79 | CNR1 (0.45) | KDM5AKDM4CDUTTLR4TLR2 | |
| SCHEMBL1034790 | 0.79 | SLC2A1 (0.59) | — | |
| SCHEMBL16902898 | 0.79 | KDM5A (0.48) | KDM5AKDM4CTLR4TLR2NR1H4 | |
| SCHEMBL6851212 | 0.79 | TLR4 (0.47) | KDM5AKDM4CALDH1A1TLR4TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3580220-B1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | KDM5A 1183/4885KDM4C 2307/4885NOS1 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.